Provided by Tiger Trade Technology Pte. Ltd.

Apellis Pharmaceuticals Inc.

22.58
-0.2500-1.10%
Post-market: 22.580.00000.00%16:10 EST
Volume:1.27M
Turnover:29.00M
Market Cap:2.86B
PE:63.05
High:23.18
Open:23.12
Low:22.51
Close:22.83
52wk High:30.48
52wk Low:16.10
Shares:126.53M
Float Shares:78.12M
Volume Ratio:0.49
T/O Rate:1.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3581
EPS(LYR):-1.5970
ROE:14.10%
ROA:5.13%
PB:7.12
PE(LYR):-14.14

Loading ...

Apellis Pharmaceuticals (APLS) Receives a Buy from Citi

TIPRANKS
·
Jan 15

Wedbush Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)

TIPRANKS
·
Jan 13

Apellis price target lowered to $35 from $39 at Cantor Fitzgerald

TIPRANKS
·
Jan 13

Wells Fargo Sticks to Its Buy Rating for Apellis Pharmaceuticals (APLS)

TIPRANKS
·
Jan 13

Apellis Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
Jan 13

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)

TIPRANKS
·
Jan 13

Apellis falls -17.3%

TIPRANKS
·
Jan 13

Apellis posts FY2025 U.S. net product revenues of USD 689 million with SYFOVRE generating USD 587 million

Reuters
·
Jan 12

Should You Be Concerned About Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) ROE?

Simply Wall St.
·
Jan 09

S&P 500 Hits New Record Highs, Alphabet Dethrones Apple: What's Moving Markets Wednesday?

Benzinga
·
Jan 08

Apellis Pharmaceuticals Inc : Stifel Cuts Target Price to $48 From $55

THOMSON REUTERS
·
Dec 19, 2025

U.S. RESEARCH ROUNDUP-Carmax, Cintas, Nike

Reuters
·
Dec 19, 2025

Apellis Pharmaceuticals General Counsel David O. Watson Reports Sale of Common Shares

Reuters
·
Dec 19, 2025

Is Apellis Pharmaceuticals Attractive After Recent 26% Surge Despite Mixed Valuation Signals?

Simply Wall St.
·
Dec 13, 2025

Sobi Wins Positive CHMP Opinion for Aspaveli in Rare Kidney Diseases

Reuters
·
Dec 12, 2025

Apellis Reports Positive Phase 3 Results for Its Kidney Disease Treatment Empaveli

MT Newswires Live
·
Dec 04, 2025

Apellis Wins FDA Approval for EMPAVELI in Rare Kidney Diseases

Reuters
·
Dec 04, 2025

Assessing Apellis Pharmaceuticals (APLS) Valuation Following Five-Year SYFOVRE Efficacy Data in Geographic Atrophy

Simply Wall St.
·
Dec 03, 2025

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

Reuters
·
Nov 25, 2025

Apellis Pharmaceuticals General Counsel David Watson Reports Sale of Common Shares

Reuters
·
Nov 18, 2025